{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:34:41Z","timestamp":1792596881790,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inhibiting tubular urate reabsorption may protect the kidney from urate-induced tubular injury. However, this approach may promote intratubular uric acid crystallization, especially in acidified urine, which could be toxic to the kidney. To assess how tubular urate handling affects kidney outcomes, we conducted a retrospective cohort study including 1042 patients with estimated glomerular filtration rates (eGFR) of 15\u201360\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>. The exposures were fractional excretion of uric acid (FEUA) and urinary uric acid-to-creatinine ratio (UUCR). The kidney outcome was defined as a halving of eGFR from baseline or initiating kidney replacement therapy. The median FEUA and UUCR were 7.2% and 0.33\u00a0g\/gCre, respectively. During a median follow-up of 1.9\u00a0years, 314 kidney outcomes occurred. In a multivariate Cox model, the lowest FEUA quartile exhibited a 1.68-fold higher rate of kidney outcome than the highest FEUA quartile (95% confidence interval, 1.13\u20132.50; P\u2009=\u20090.01). Similarly, lower UUCR was associated with a higher rate of kidney outcome. Notably, patients in the highest quartile of FEUA and UUCR were at the lowest risk of kidney outcome even among those with aciduria. In conclusion, lower FEUA and UUCR were associated with a higher risk of kidney failure, suggesting that increased urate reabsorption is harmful to the kidney.<\/jats:p>","DOI":"10.1038\/s41598-024-55809-9","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T15:03:47Z","timestamp":1709305427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Association between urinary uric acid excretion and kidney outcome in patients with CKD"],"prefix":"10.1038","volume":"14","author":[{"given":"Yuta","family":"Asahina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsufumi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mizui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ya","family":"Kaimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"55809_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.semarthrit.2012.09.009","volume":"42","author":"SP Juraschek","year":"2013","unstructured":"Juraschek, S. P., Kovell, L. C., Miller, E. R. 3rd. & Gelber, A. C. Association of kidney disease with prevalent gout in the United States in 1988\u20131994 and 2007\u20132010. Semin Arthritis Rheum. 42, 551\u2013561 (2013).","journal-title":"Semin Arthritis Rheum."},{"key":"55809_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2012.07.021","volume":"61","author":"DI Jalal","year":"2013","unstructured":"Jalal, D. I., Chonchol, M., Chen, W. & Targher, G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 61, 134\u2013146 (2013).","journal-title":"Am J Kidney Dis."},{"key":"55809_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","volume":"15","author":"Y Sato","year":"2019","unstructured":"Sato, Y. et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat. Rev. Nephrol. 15, 767\u2013775 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"55809_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki, K. et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am. J. Kidney Dis. 44, 642\u2013650 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","volume":"50","author":"M Chonchol","year":"2007","unstructured":"Chonchol, M. et al. Relationship of uric acid with progression of kidney disease. Am. J. Kidney Dis. 50, 239\u2013247 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr, R. P. et al. Elevated uric acid increases the risk for kidney disease. J. Am. Soc. Nephrol. 19, 2407\u20132413 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55809_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"CY Hsu","year":"2009","unstructured":"Hsu, C. Y., Iribarren, C., McCulloch, C. E., Darbinian, J. & Go, A. S. Risk factors for end-stage renal disease: 25-year follow-up. Arch. Intern. Med. 169, 342\u2013350 (2009).","journal-title":"Arch. Intern. Med."},{"key":"55809_CR8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2337\/dc10-0227","volume":"33","author":"LH Ficociello","year":"2010","unstructured":"Ficociello, L. H. et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up. Diabetes Care 33, 1337\u20131343 (2010).","journal-title":"Diabetes Care"},{"key":"55809_CR9","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1093\/ndt\/gfq740","volume":"26","author":"IZ Ben-Dov","year":"2011","unstructured":"Ben-Dov, I. Z. & Kark, J. D. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research Clinic cohort study. Nephrol. Dial. Transplant. 26, 2558\u20132566 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55809_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000326848","volume":"33","author":"H Sonoda","year":"2011","unstructured":"Sonoda, H., Takase, H., Dohi, Y. & Kimura, G. Uric acid levels predict future development of chronic kidney disease. Am. J. Nephrol. 33, 352\u2013357 (2011).","journal-title":"Am. J. Nephrol."},{"key":"55809_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero, M. et al. Uric acid and long-term outcomes in CKD. Am. J. Kidney Dis. 53, 796\u2013803 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.exger.2008.01.006","volume":"43","author":"G Sturm","year":"2008","unstructured":"Sturm, G. et al. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp. Gerontol. 43, 347\u2013352 (2008).","journal-title":"Exp. Gerontol."},{"key":"55809_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002725","volume":"16","author":"DM Jordan","year":"2019","unstructured":"Jordan, D. M. et al. No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study. PLoS Med. 16, e1002725. https:\/\/doi.org\/10.1371\/journal.pmed.1002725 (2019).","journal-title":"PLoS Med."},{"key":"55809_CR14","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve, S. V. et al. Effects of allopurinol on the progression of chronic kidney disease. N. Engl. J. Med. 382, 2504\u20132513 (2020).","journal-title":"N. Engl. J. Med."},{"key":"55809_CR15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria, A. et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N. Engl. J. Med. 382, 2493\u20132503 (2020).","journal-title":"N. Engl. J. Med."},{"key":"55809_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ekir.2022.11.016","volume":"8","author":"RJ Johnson","year":"2022","unstructured":"Johnson, R. J., Sanchez Lozada, L. G., Lanaspa, M. A., Piani, F. & Borghi, C. Uric acid and chronic kidney disease: Still more to do. Kidney Int. Rep. 8, 229\u2013239 (2022).","journal-title":"Kidney Int. Rep."},{"key":"55809_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.ajkd.2022.08.001","volume":"81","author":"RJ Johnson","year":"2023","unstructured":"Johnson, R. J. Intestinal hyperuricemia as a driving mechanism for CKD. Am. J. Kidney Dis. 81, 127\u2013130 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2022.05.010","volume":"81","author":"Y Ohashi","year":"2023","unstructured":"Ohashi, Y. et al. Urate transporter ABCG2 function and asymptomatic hyperuricemia: A retrospective cohort study of CKD Progression. Am. J. Kidney Dis. 81, 134\u2013144 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep39884","volume":"7","author":"TT Braga","year":"2017","unstructured":"Braga, T. T. et al. Soluble uric acid activates the NLRP3 inflammasome. Sci. Rep. 7, 39884 (2017).","journal-title":"Sci. Rep."},{"key":"55809_CR20","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3892\/ijmm.2015.2148","volume":"35","author":"J Xiao","year":"2015","unstructured":"Xiao, J. et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1beta expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int. J. Mol. Med. 35, 1347\u20131354 (2015).","journal-title":"Int. J. Mol. Med."},{"key":"55809_CR21","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/emboj.2013.171","volume":"32","author":"I Maejima","year":"2013","unstructured":"Maejima, I. et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J. 32, 2336\u20132347 (2013).","journal-title":"EMBO J."},{"key":"55809_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115210","volume":"9","author":"D Verzola","year":"2014","unstructured":"Verzola, D. et al. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS\u00a0One 9, e115210. https:\/\/doi.org\/10.1371\/journal.pone.0115210 (2014).","journal-title":"PLoS\u00a0One"},{"key":"55809_CR23","doi-asserted-by":"publisher","first-page":"F471","DOI":"10.1152\/ajprenal.00560.2012","volume":"304","author":"ES Ryu","year":"2013","unstructured":"Ryu, E. S. et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am. J. Physiol. Renal Physiol. 304, F471\u2013F480 (2013).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"55809_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2215\/CJN.11480821","volume":"17","author":"DLS Suijk","year":"2022","unstructured":"Suijk, D. L. S. et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin. J. Am. Soc. Nephrol. 17, 663\u2013671 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"55809_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","volume":"98","author":"J Li","year":"2020","unstructured":"Li, J. et al. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 98, 769\u2013777 (2020).","journal-title":"Kidney Int."},{"key":"55809_CR26","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1681\/ASN.2020040523","volume":"31","author":"M Sellmayr","year":"2020","unstructured":"Sellmayr, M. et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J. Am. Soc. Nephrol. 31, 2773\u20132792 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55809_CR27","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/sim.4780040112","volume":"4","author":"J Cuzick","year":"1985","unstructured":"Cuzick, J. A Wilcoxon-type test for trend. Stat. Med. 4, 87\u201390 (1985).","journal-title":"Stat. Med."},{"key":"55809_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2018.21554","volume":"321","author":"S Haneuse","year":"2019","unstructured":"Haneuse, S., VanderWeele, T. J. & Arterburn, D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA 321, 602\u2013603 (2019).","journal-title":"JAMA"},{"key":"55809_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1536867X20909696","volume":"20","author":"A Linden","year":"2020","unstructured":"Linden, A., Mathur, M. B. & VanderWeele, T. J. Conducting sensitivity analysis for unmeasured confounding in observational studies using E-values: The evalue package. Stata J. 20, 162\u2013175 (2020).","journal-title":"Stata J."},{"key":"55809_CR31","doi-asserted-by":"publisher","first-page":"j4587","DOI":"10.1136\/bmj.j4587","volume":"359","author":"MA Mansournia","year":"2017","unstructured":"Mansournia, M. A., Etminan, M., Danaei, G., Kaufman, J. S. & Collins, G. Handling time varying confounding in observational research. BMJ 359, j4587. https:\/\/doi.org\/10.1136\/bmj.j4587 (2017).","journal-title":"BMJ"},{"key":"55809_CR32","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/ije\/dyx086","volume":"46","author":"AI Naimi","year":"2017","unstructured":"Naimi, A. I., Cole, S. R. & Kennedy, E. H. An introduction to g methods. Int. J. Epidemiol. 46, 756\u2013762 (2017).","journal-title":"Int. J. Epidemiol."},{"key":"55809_CR33","first-page":"1620","volume":"33","author":"HW Chou","year":"2018","unstructured":"Chou, H. W. et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: A 13-year inception cohort study. Nephrol. Dial. Transplant. 33, 1620\u20131627 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55809_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.ajkd.2020.09.009","volume":"77","author":"AG Stack","year":"2021","unstructured":"Stack, A. G. et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: A randomized trial. Am. J. Kidney Dis. 77, 481\u2013489 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10067-014-2806-9","volume":"35","author":"L Ma","year":"2016","unstructured":"Ma, L. et al. Influence of urate-lowering therapies on renal handling of uric acid. Clin. Rheumatol. 35, 133\u2013141 (2016).","journal-title":"Clin. Rheumatol."},{"key":"55809_CR36","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1053\/j.ajkd.2016.11.006","volume":"69","author":"MA Lusco","year":"2017","unstructured":"Lusco, M. A., Fogo, A. B., Najafian, B. & Alpers, C. E. AJKD atlas of renal pathology: Gouty nephropathy. Am. J. Kidney Dis. 69, e5\u2013e6. https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.006 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"55809_CR37","first-page":"1306","volume":"28","author":"Y Moriwaki","year":"2001","unstructured":"Moriwaki, Y. et al. Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout. J. Rheumatol. 28, 1306\u20131310 (2001).","journal-title":"J. Rheumatol."},{"key":"55809_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.7326\/0003-4819-91-1-44","volume":"91","author":"PA Simkin","year":"1979","unstructured":"Simkin, P. A., Hoover, P. L., Paxson, C. S. & Wilson, W. F. Uric acid excretion: Quantitative assessment from spot, midmorning serum and urine samples. Ann. Intern. Med. 91, 44\u201347 (1979).","journal-title":"Ann. Intern. Med."},{"key":"55809_CR39","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida, K. et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 3, 764 (2012).","journal-title":"Nat. Commun."},{"key":"55809_CR40","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s10157-018-1586-y","volume":"22","author":"H Yu","year":"2018","unstructured":"Yu, H. et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: A prospective pilot study. Clin. Exp. Nephrol. 22, 1324\u20131330 (2018).","journal-title":"Clin. Exp. Nephrol."},{"key":"55809_CR41","doi-asserted-by":"publisher","first-page":"R189","DOI":"10.1186\/ar4020","volume":"14","author":"DR Kannangara","year":"2012","unstructured":"Kannangara, D. R. et al. Fractional clearance of urate: Validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Res. Ther. 14, R189 (2012).","journal-title":"Arthritis Res. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55809-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55809-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55809-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T15:06:10Z","timestamp":1709305570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55809-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55809"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55809-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5119"}}